Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context

Nektar REZPEG Pipeline Update: Three Phase 2 Trials in Autoimmune Disease

Nektar Therapeutics pipeline update: REZPEG clinical programs and regulatory context, with trial facts, status, and a clear split between active development and regulatory context. Three Phase 2 studies are currently active or recruiting across atopic dermatitis, alopecia areata, and type 1 diabetes.

IntelligenceRegulatory Impact▾

FDA and EMA decisions frame this story. Regulatory relevance is medium for atopic dermatitis, with rezpegaldesleukin and REZPEG most exposed. Track designations, submission types, and label or guidance shifts that could move timelines.

Key Takeaways

• Rezpegaldesleukin (REZPEG, or NKTR-358) is a first-in-class regulatory T cell stimulator being developed by Nektar Therapeutics.
• Nektar is advancing rezpegaldesleukin for atopic dermatitis, alopecia areata, and type 1 diabetes.
• Two Phase 2b trials—NCT06136741 in atopic dermatitis and NCT06340360 in alopecia areata—are active but not recruiting; a Phase 2 trial in type 1 diabetes (NCT07142252) is currently recruiting.

IntelligenceCompetitive Intelligence▾

Competitive pressure is high. Nektar Therapeutics reshape positioning, formulary leverage, and partnership options. Benchmark pipeline differentiation and regional market access assumptions against this development.

REZPEG Clinical Trial Footprint

Nektar Therapeutics is conducting three Phase 2 studies of rezpegaldesleukin across three distinct indications. Each trial has a specific NCT identifier, indication, and enrollment status as recorded on ClinicalTrials.gov.

NCT06136741 is a Phase 2b study evaluating rezpegaldesleukin in adult patients with moderate-to-severe atopic dermatitis. This trial is active but not recruiting.

NCT06340360 is a Phase 2b study evaluating rezpegaldesleukin in the treatment of severe to very severe alopecia areata in adult patients. This trial is active but not recruiting.

NCT07142252 is a Phase 2 study of rezpegaldesleukin in new-onset type 1 diabetes mellitus, sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). This trial is currently recruiting.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance medium for atopic dermatitis. Expect implications for pricing, access, and launch sequencing.

Mechanism and Clinical Rationale

Rezpegaldesleukin is described as a first-in-class regulatory T cell stimulator. It is being investigated for its potential to provide long-term, treatment-free disease control in cutaneous disease therapy. The mechanism targets a specific immune pathway relevant to inflammatory and autoimmune conditions.

IntelligenceStrategic Takeaways▾

Rezpegaldesleukin (REZPEG, or NKTR-358) is a first-in-class regulatory T cell stimulator being developed by Nektar Therapeutics. Nektar is advancing rezpegaldesleukin for atopic dermatitis, alopecia areata, and type 1 diabetes . Two Phase 2b trials— NCT06136741 in atopic dermatitis and NCT06340360 in alopecia areata —are active but not recruiting; a Phase 2 trial in type 1 diabetes (NCT07142252) is currently recruiti

Trial Status and Development Stage

Rezpegaldesleukin remains in Phase 2 clinical development. NCT06136741 and NCT06340360 are both active but not recruiting, indicating that enrollment has closed or reached capacity and the trials are in an ongoing data collection or follow-up phase. NCT07142252 is actively recruiting patients, meaning enrollment is still open for new participants.

Trial status—whether active, recruiting, completed, or suspended—reflects the operational state of a study. Active status means the trial is underway; recruiting status means sites are actively enrolling; active but not recruiting means enrollment is closed but the trial continues. None of these statuses indicate regulatory approval or clearance.

IntelligenceEvidence Quality▾

Grounded in 1 peer-reviewed source.

What Analysts and BD Teams Should Track

For competitive benchmarking, analysts and business development teams should monitor the three trial identifiers on ClinicalTrials.gov: NCT06136741, NCT06340360, and NCT07142252. Track changes in recruitment status, completion dates, and any new trial registrations or closures. These trial records are the primary source of information on rezpegaldesleukin's clinical development progress.

Evaluation of clinical-stage programs should be grounded in trial facts: phase designation, indication, sponsor, enrollment status, and trial ID. Efficacy, safety, or commercial potential cannot be determined from trial status alone and should only be assessed when clinical data are published or formally disclosed.

Regulatory Context

Rezpegaldesleukin has not received regulatory approval from the FDA or other regulatory agencies for any indication. The drug remains in Phase 2 clinical evaluation. Clinical development stage does not predict approval, timeline, or outcome. Regulatory decisions are made only after complete clinical data are submitted and reviewed by the appropriate regulatory authority.

Frequently Asked Questions